Eledon Pharmaceuticals
ELDN
16 hedge funds and large institutions have $5.43M invested in Eledon Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 6 closing their positions.
0.3% less ownership
Funds ownership: 2.3% → 2% (-0.3%)
20% less funds holding
Funds holding: 20 → 16 (-4)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
70% less capital invested
Capital invested by funds: $18.2M → $5.43M (-$12.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$267K |
| 2 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$17.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.76K |
| 4 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
+$510 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$1.48M |
| 2 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$421K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$330K |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$91K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$78.1K |
ELDN Hedge Fund Activity: Q4 2018 in Review
16 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2018, worth a combined $5.43M — down 70% from $18.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELDN and 2 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was B. Riley Wealth Advisors, adding an estimated $267K. The largest seller was RTW Investments, exiting entirely with an estimated $1.48M sold.
- 16 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2018, down from 20 in Q3 2018.
- Funds reported $5.43M of Eledon Pharmaceuticals stock for Q4 2018, down 70% quarter-over-quarter.
- 2 funds opened new Eledon Pharmaceuticals positions in Q4 2018 and 6 closed out, a net change of -4 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2018 was B. Riley Wealth Advisors, an estimated $267K added.
- The largest Eledon Pharmaceuticals seller in Q4 2018 was RTW Investments, an estimated $1.48M sold.
Based on aggregated 13F filings for Q4 2018.